The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Colorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard first-line treatment for advanced pMMR colorectal cancer. The inclusion of anti-EGFR or anti-VEGF targeted therapies has improved the overall survival of advanced colorectal cancer patients from 13 months in the era of fluorouracil monotherapy to the current 30 months. However, many patients refuse chemotherapy or cannot tolerate cytotoxic chemotherapeutic drugs, which of

Trial Details

NCT ID
NCT07257653
Phase
PHASE2
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Cetuximab β；Fruquintinib；
  • Cetuximab β；Fruquintinib；anti-PD1 antibody；
  • Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • 1）Subjects voluntarily join this study, sign the informed consent form, and demonstrate good compliance; 2) Age: 10-80 years old, ECOG PS score of …
  • Hematological examination standards (no blood transfusion or use of hematopoietic growth factors for correction within 7 days prior to screening):
  • Hemoglobin (HGB) ≥ 90 g/L;
  • Absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹/L;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →